MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.31B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 2.12M
Average 5.73M
MNKD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MannKind CorporationNASDAQ: MNKD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$16.62M, compared with $13.16M a year earlier. Trailing-twelve-month net income was -$23.91M.
Context
- Net income amounted to 1.7% of revenue in FY2025, down 8.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$57.78M (-1085.5%) for the fiscal year ending Dec 2026, a slowdown from the -78.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.62M+4.2% QoQ
- Last fiscal yearDec 2025
- $5.86M-78.7% YoY
- LTMMar 2026
- -$23.91M-179.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -226.3% | -459.5% | -233.2 pp |
| 1 year | -78.7% | -1085.5% | -1006.7 pp |
| 3-year CAGR | — | +87.6% | — |
| 5-year CAGR | +81.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 5.86M USD
- Year-over-year change
- -78.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.86M | -78.7% |
| FY2024 | 2024-12-31 | 27.59M | +331.1% |
| FY2023 | 2023-12-31 | (11.94M) | +86.3% |
| FY2022 | 2022-12-31 | (87.4M) | -8.0% |
| FY2021 | 2021-12-31 | (80.93M) | — |
Net Income vs competitors
How MNKD compares with its peers on the latest reported figures
- MNKD's LTM Mar 2026 net income of $23.91M is the 5th largest of the 6 companies compared; the peer median is $12.01M.
- Its year-over-year change of -179.4% is the lowest of 6, against a peer median of +296.4%.
- Net income amounts to 6.6% of revenue for MNKD, versus a peer median of 152.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $197.98M | +1165.0% | +70.3% | 200.0% |
| LTM Mar 2026 | $114.54M | +296.4% | — | 104.3% | |
| LTM Mar 2026 | $110M | +489.6% | — | — | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $23.91M | -179.4% | — | 6.6% | |
| LTM Mar 2026 | $12.01M | +126.6% | — | 3.8% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding MNKD) | $12.01M | +296.4% | +30.0% | 152.2% | |
Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.93M) | (87.4M) | (11.94M) | 27.59M | 5.86M |
| Depreciation & Amortization | 5.47M | 6.29M | 5.8M | 9.04M | 12.28M |
| Deferred Income Tax | 12.64M | 0 | 0 | 0 | (4.97M) |
| Stock-Based Compensation | 12.2M | 0 | 17.65M | 21.36M | 24.2M |
| Change in Working Capital | (17.73M) | (24.05M) | 14.63M | (36.47M) | (86.35M) |
| Accounts Receivables | (776K) | (11.81M) | 2.35M | 2.65M | (4.76M) |
| Inventory | (4.08M) | (5.67M) | 4.57M | (3.2M) | 10.4M |
| Accounts Payables | 1.37M | 4.1M | (1.47M) | (2.79M) | (16.71M) |
| Other Working Capital | (14.25M) | (10.67M) | 9.18M | (33.14M) | (75.27M) |
| Other Non-Cash Items | 6.63M | 24.47M | 7.96M | 21M | 67.23M |
| Operating Cash Flow | (61.71M) | (80.7M) | 34.09M | 42.51M | 18.26M |
| Capital Expenditures | (11.47M) | (7.59M) | (42.44M) | (9.69M) | (4.57M) |
| Acquisitions (Net) | (56.06M) | (15.34M) | 0 | 0 | (347.74M) |
| Purchases of Investments | (199.13M) | (5M) | (79.1M) | (273.79M) | (157.8M) |
| Sales of Investments | 59.06M | 0 | 119.17M | 58.13M | 221.72M |
| Other Investing Activities | 56.06M | 32.8M | 382K | 128.71M | (16.41M) |
| Investing Cash Flow | (151.54M) | 4.87M | (1.99M) | (96.65M) | (304.8M) |
| Debt Repayment | 281.08M | (1.09M) | (6.86M) | (133.17M) | 325M |
| Common Stock Issued | 1.89M | 22.56M | 6.89M | (6.09M) | 1.99M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.7M) | (62K) | 136.58M | 1.99M | (11.89M) |
| Financing Cash Flow | 270.27M | 21.41M | 136.61M | (137.27M) | 315.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 57.02M | (54.42M) | 168.71M | (191.4M) | 28.55M |
| Free Cash Flow | (73.18M) | (88.29M) | (8.35M) | 32.82M | 13.69M |
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$4.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.